CYROLITE® Compounds News

Evonik Cyro Introduces Acrylic-Based Multipolymer Compound For Antimicrobial Medical Device Designs

Anaheim, CA, USA – February 8, 2011
  • CYROLITE® Protect Specifically Developed for FDA Regulated Class I or Class II Medical Devices Covered by 510(k) PMN Submission

Anaheim, CA – February 8, 2011 - Evonik Cyro, LLC (booth #620) introduces CYROLITE® Protect, an acrylic-based multipolymer compound that has been specifically developed for medical devices that include antimicrobial agents, at MD&M West at the Anaheim Convention Center, February 8-10. Expressly designed for FDA regulated Class I or Class II medical devices covered by 510(k) PMN submission, CYROLITE® Protect is particularly well suited for Luer connectors, spikes, Y-sites, check valves and filter housings.

CYROLITE® Protect acrylic-based multipolymer compound provides antimicrobial capabilities* against a variety of microorganisms commonly found in healthcare facilities. It is the latest addition to the family of CYROLITE® acrylic-based multipolymer compounds, the world’s most advanced medical acrylics. Offering a superior balance of properties, CYROLITE® compounds empower designers to create better-than-ever medical devices.

“With the introduction of CYROLITE® Protect, Evonik Cyro is leading the way in transparent antimicrobial products. Through extensive test methods, we have been able to develop a compound that addresses a growing concern in the medical industry,” said Peter Allread, General Manager, Performance Polymers/Molding Compounds. “In recent years there has been interest in adding antimicrobial agents to medical devices to help reduce or prevent device-related infection. CYROLITE® Protect has been specifically developed to address this issue.”

CYROLITE® Protect is a tough acrylic-based multipolymer compound that has other design advantages. It has excellent mechanical, thermal, and optical properties that meet various ASTM Standards.

The CYROLITE® Protect compound is available in a transparent green tint in pellet form and is easy to process, making it ideal for processing with either traditional injection molding or extrusion lines with 3-zone general purpose screws.

Another benefit of the CYROLITE® Protect compound is its chemical resistant properties as well as resistance to plasticizers found in flexible PVC tubing. It is also free of bisphenol A (BPA). CYROLITE® Protect can be sterilized with gamma, e-beam and EtO technologies.

In addition to CYROLITE® Protect, Evonik Cyro is exhibiting a full range of CYROLITE® and ACRYLITE® advanced acrylic polymers for medical devices/diagnostics, as well as VESTAMID® polyamide elastomer compounds for catheters/tubing, TROGAMID® CX for infusion/transfusion components, and biomedical VESTAKEEP® PEEK granules and powders for short and long-term contact implantation devices.

 

* As tested by the JIS Z 2801 protocol. 

CYROLITE® Protect, an acrylic-based multipolymer compound for antimicrobial medical device designs.

CYROLITE® Protect, an acrylic-based multipolymer compound for antimicrobial medical device designs.

Evonik Industries is the creative industrial group from Germany. In our core business of specialty chemicals, we are a global leader. In addition, Evonik is an expert in power generation from hard coal and renewable energies, and one of the largest private residential real estate companies in Germany. Our company’s performance is shaped by creativity, specialization, continuous self-renewal, and reliability.

Evonik is active in over 100 countries around the world. In its fiscal year 2009 about 39,000 employees generated sales of about €13.1 billion and an operating profit (EBITDA) of about €2.0 billion.

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

Downloads

Contact

Gail J. Wood

Contact

Larry Gabriel

Contact